Business
Spectral AI Announces 2024 Fourth Quarter and Full Year Financial Results
2024 Research & Development Revenue of $30 Million Successful Results from the US Burn Validation Study On Track for Regulatory Submission in US for DeepView™ System DALLAS, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (“AI”) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2024”) and full year (“FY
About this update from Spectral Ai, Inc.
[{"type":"image","alt":"Spectral AI, Inc.","displaySize":"","headline":null,"caption":"Spectral AI, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":78,"url":"https://media.zenfs.com/en/globenewswire.com/23a9fc91c43a2f0647ed42a9076103ab"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NMHcc5qGUB2OTcJyeAvzUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/23a9fc91c43a2f0647ed42a9076103ab","width":150,"height":78}},"lazy":false},{"type":"text","content":"2024 Research & Development Revenue of $30 Million","length":54,"tagName":"p"},{"type":"text","content":"Successful Results from the US Burn Validation Study ","length":52,"tagName":"p"},{"type":"text","content":"On Track for Regulatory Submission in US for DeepView™ System ","length":66,"tagName":"p"},{"type":"text","content":"DALLAS, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (“AI”) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2024”) and full year (“FY 2024”) ended December 31, 2024, and provided an update on its ongoing business activities.","length":425,"tagName":"p"},{"type":"text","content":"“Spectral AI achieved much in 2024. Our top-line revenue reflects extensive work on our BARDA PBS contract, and our progress along multiple fronts has continued into 2025,” said Dr. J. Michael DiMaio, M.D., the Company’s Chairman of the Board. “The team’s achievements to date, and those on the horizon, are the result of a 10-year record of success in delivering on a promise to the US government and the American people to develop and commercialize our proprietary AI-Driven DeepView™ System wound healing assessment platform, a technology that we believe can help change the standard of care while delivering value across the healthcare ecosystem. We expect to realize our first commercial product revenue in the second half of this year. Given the pace of our product development and clinical activities in the US and internationally, we believe that we are on the proper path to generate commercial revenue across four separate DeepView System platforms covering burn and other indications within the next three year...